Smoking Impairs Methotrexate Efficacy Save
The Journal of Rheumatology reports that current smoking significantly reduces the clinical efficacy of methotrexate (MTX)-based therapy, as studied in an early rheumatoid arthritis (RA) cohort.
Using data from the CAMERA-II trial (which included early RA patients) they studied MTX treated patients who were randomized to concomitant prednisone (MTX + pred) or placebo (MTX + PBO) for 24 months.
Smoking was significantly associated with higher DAS28 over time and was not affected by prednisone use.The negative effect of current smoking on DAS28 was dose dependent.
Current smoking reduces the clinical effect of MTX-based strategies.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.